[1]
Supuran, C.T. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov., 2008, 7, 168-181.
[2]
Mincione, F.; Menabuoni, L.; Supuran, C.T. Clinical applicationsof the Carbonic anhydrase inhibitors in ophthalmology. In: Supuran C, Scozzafava A, Conway J, Eds. Carbonic anhydrase, its inhibitors and activators; Boca Raton (FL): CRC Press, 2004; pp. 243-254.
[3]
Supuran, C.T.; Scozzafava, A.; Conway, J., Eds.; Carbonicanhydrase-its inhibitors and activators; Boca Raton, USA: CRC Press, 2004, pp. 1-363.
[4]
Clare, B.W.; Supuran, C.T. Boca Raton, FI; USA: CRC Press, 2004.
[5]
Jiang, Y-R.; Chen, Y-L.; Yang, Y-Y.; Liu, Q. Quantitative structure-activity relationship of 2-alkyl-4-(biphenylylmethoxy) pyridine 5derivatives with AT1 receptor antagonistic activity. J. Cent. South Univ., 2012, 19(5), 1212-1218.
[6]
Nordfors, K.; Haapasalo, J.; Korja, M. The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis. BMC Can, 2010, 10, 148-158.
[7]
Chien, M.H.; Ying, T.H.; Hsieh, Y.H. Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis. Oral Oncol., 2012, 48, 417-423.
[8]
Zubriene, A.; Edita, C.; Joana, G.; Migle, K.; Sigitas, T.; Daumantas, M. Benzene sulphonamides with benzimidazole moieties as inhibitors of carbonic anhydrase I, II, VII, XII and XIII. J. Enz Inhib. Med. Chem., 2014, 29(1), 124-131.
[9]
Garaj, V.; Puccetti, L. Giuseppe.; Fasolis, Winum, J.Y. Carbonic anhydrase inhibitors: Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg. Med. Chem. Lett., 2005, 15, 3102-3108.
[10]
Supuran, C.T.; Innocenti, A.; Mastrolorenzo, A.; Scozzafava, A. Antiviral sulfonamide derivatives. Mini Rev. Med. Chem., 2004, 4, 189-200.
[11]
Carta, F.; Scozzafava, A.; Supuran, C.T. Sulfonamides: A patent review (2008-2012). Expert Opin. Ther. Pat., 2012, 22, 747-758.
[12]
Singh, S. A Comparative Molecular Field (CoMFA) Studies on Carbonic Anhydrase Inhibitor hCA IX—Tumor-Associated (Hypoxia). Lett. Drug Des. Discov., 2011, 8, 877-883.
[13]
Singh, S. In silico molecular modeling of Carbonic anhydrase inhibitors: Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic/heterocyclic sulfonamides. Bioorg. Med. Chem. Lett., 2015, 25, 133-141.
[14]
Singh, S.; Supuran, C.T. 3D-QSAR CoMFA studies on sulfonamide inhibitors of the Rv3588c β-carbonic anhydrase from Mycobacterium tuberculosis and design of not yet synthesized new molecules. J. Enz. Inhib. Med. Chem., 2014.
[15]
Geladi, P. Notes on the history and nature of partial least squares (PLS) modeling. J. Chem., 1988, 2, 231-246.
[16]
Cramer, R.D. III.; Bunce, J.D.; Patterson, D.E. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR. Quant. Struct. Act. Relat., 1988, 7, 18-25.
[17]
Thaimattam, R. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies. Bioorg. Med. Chem., 2004, 1215.
47
5
1
1